Multiple endpoint comparisons favoured the rolapitant group compared with the active control group. Although some endpoints are interdependent (eg, no emesis is part of the complete response endpoint), these endpoints are used routinely in other similar clinical trials to assess different aspects of chemotherapy-induced nausea and vomiting symptoms and are clinically meaningful.